Prognostic value of Serum miR-217 Level in Osteosarcoma Patients

Jia Ye  
renmin hospital of wuhan university

Zhi-Hui Jin  
Renmin Hospital of Wuhan University: Wuhan University Renmin Hospital

Ren Chen  
renmin hospital of wuhan universtiy

Sen Chen  
renmin hospital of wuhan university

Yi-Jun Ren  
renming hospital of wuhan university

Wei-Chun Guo  
renmin hospital of wuhan universtiy

Hui He (✉ hehui880@126.com)  
the First People’s Hospital of Jiangxia District  https://orcid.org/0000-0001-8055-1547

Research

Keywords: Serum miR-217, prognosis, osteosarcoma, microRNA, diagnosis, survival

DOI: https://doi.org/10.21203/rs.3.rs-111272/v2

License: ☝️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: MicroRNA (miR)-217 is a tumor suppressor significantly associated with osteosarcoma. We try to evaluate serum levels miR-217 in osteosarcoma patients and evaluate its prognostic significance.

Methods: A total of 163 consecutive osteosarcoma patients and 96 healthy participates were enrolled. Serum miR-217 levels were evaluated by using real-time quantitative reverse transcription polymerase chain reactions (RT-PCR). The association between serum miR-217 level and survival outcomes was evaluated by univariate and multivariate analysis.

Results: Serum miR-217 levels in osteosarcoma patients was significantly lower than healthy volunteers (P<0.05). Low serum miR-217 was significantly related to advanced cancer and metastasis (both P<0.05). Moreover, patients with a low serum miR-217 had a poorer overall survival than those with a high serum miR-217 levels (P<0.05). Serum miR-217 level also been showed as independent risk factor for osteosarcoma in multivariate analysis (HR, 0.42; 95%CI: 0.12–0.98; p<0.01).

Conclusions: Serum miR-217 levels was signicantly downregulated in osteosarcoma patients and remarkably associated with poor prognosis, indicating that serum miR-217 might serve as a useful diagnostic and prognostic indicator for osteosarcoma.

Introduction

Osteosarcoma is one of the most common and lethal primary sarcoma of the bone in adolescents. Despite considerable advancements of therapeutic and diagnostic strategies over the previous decades, the long-term prognosis of osteosarcoma remains unsatisfactory, with 5-year survival rates less than 60%, even with the use of combined chemotherapy. Recurrent and metastasis were considered the main contributors to the low 5-year survival rates in patients with osteosarcoma. Lung metastasis is frequently observed in newly diagnosed osteosarcoma, approximately 10–20% of patients are diagnosed with metastatic OS upon identification of the disease. Moreover, the potential molecular mechanisms underlying the histological heterogeneity, response to treatments and recurrent are still unclear. Therefore, furtherly understanding of the complex and definite molecular mechanisms concerning the progression and aggressiveness of osteosarcoma is important for risk stratification and individual treatment.

MicroRNAs (miRNAs) is a subset of endogenous small non-coding RNAs, and is released though passive leakage from cells in setting of chronic inflammation or injury, active secretion, complex formation with lipoproteins or RNA binding proteins, which can specifically regulate gene expression by inhibiting the translation and/or decreasing of the stability of specific protein-coding gene. Previous studies showed that dysregulation of miRNAs was significantly associated with development of various malignancies, including osteosarcoma. It has been revealed that miRNAs can maintain the stable state in serum samples with appropriate and measurable concentration. In details, serum miRNAs can be resistant to endogenous ribonuclease activity by being packaged into apoptotic bodies or exosomes, or
association with other molecules (e.g., in a RNA–protein complex) or modifications of the miRNAs that make them resistant to RNase activity \(^{17,18}\). In addition, the inherent regulatory function of miRNAs makes it likely that many miRNAs expressed in tumor tissue influence the biological behavior and clinical phenotype of the tumor. Thus, various serum miRNAs expression have been confirmed as valuable indictors for diagnosis or prognosis of cancer\(^{19,20}\).

MiRNA-217 is a tumor suppressor miRNA targeting several oncogenes in different cell type\(^{21,22}\). MiR-217 could serve as a tumor suppressor which can inhibit tumor growth \(^{23}\). Moreover, miR-217 could also function as a oncogene \(^{24}\). Therefore, additional studies will be needed to explore the role of miR-217 in cancers. However, no previous study has been showed to evaluate the value of miR-217 in osteosarcoma, especially for serum miR-217. Therefore, in current study, we try to evaluate serum level of miRNA-217 in osteosarcoma patients and analyze its prognostic value.

**Materials And Methods**

**Patients**

This study protocol was planned by basing on the relevant guidelines or regulations, and conformed to the Declaration of Helsinki. All subjects have provided signed informed consent prior to enrollment. This study was also approved by the ethics committee of the First People's Hospital of Jiangxia District (No.20201029). The data of 163 patients with primary osteosarcoma admitted to Department of Orthopaedics between July 1, 2014 and July 1, 2018 were retrospectively collected. Exclusion was conducted based on following criteria: preoperative comorbidity, relapse and metastasis, incomplete clinical and histopathological data and life expectancy less than 4 months. All enrolled patients received the standard preoperative neoadjuvant chemotherapy, then resection and postoperative chemotherapy according to the 2018 European Sarcoma Network Working Group Clinical Practice Guidelines for osteosarcoma\(^{25}\). The tumor specimens of all patients were pathologically diagnosed as osteosarcoma. A control group enrolled 96 age and sex-matched healthy participates.

All relevant clinical and pathological data of each patient were collected and confirmed. The clinical stages were evaluated basing on the Enneking staging system (ESS). All Patients were regularly followed up though clinical visiting or telephone. Follow-up was lasted from the enrollment to death or June 2019. the primary outcome of interest was survival status. Overall survival (OS) was defined as from the date of enrollment to the date of death or endpoint.

**RNA isolation**

Peripheral venous blood (5mL) was collected from each subject prior to treatments for osteosarcoma. Serum was extracted and transferred to RNase/DNase-free tubes and immediately stored at \(-80\ °C\) for further process. Total RNA was extracted from each serum sample by using of a miRNA easy
Serum/Plasma Kit (Qiagen, Valencia, CA, USA). The RNA concentration and integrity were evaluated using a NanoDrop ND-1000 spectrophotometer (Nanodrop technologie, USA).

**Quantification of miRNA by qRT-PCR**

Total RNA from each subject was used to reversely transcribe miRNAs to a strand cDNA by using a miScript Reverse Transcription Kit (Qiagen, Valencia, CA, USA). Amplifications were conducted by using a miScript SYBR Green PCR kit (Qiagen, Valencia, CA, USA). The RT-PCR was performed on Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Sequence of primer for miR-217 was GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACG AAA CCC A. The miR-217 expression levels in each sample were normalized against the miR-16 expression. And the threshold cycle (Ct) values ≥40 was confirmed as an undetectable level. The relative expression level of serum miR-217 was quantitatively evaluated by using the $2^{-\Delta\Delta CT}$ method.

**Statistical Analysis**

All statistical analyses were conducted by using the SPSS 20.0 (IBM, USA). The statistical results were considered as significant while P < 0.05 (two sided). Continuous variables that expressed as mean ± SD were compared by using analysis of variance (ANOVA), whereas comparisons of categorical variables were conducted by using chi-square or Fisher's exact test, which were presented as frequencies (%). Receiver operating characteristic curve (ROC) analysis was performed to evaluate the prognosis value of serum miRNA-217 levels in predicting survival. Kaplan-Meier survival curves for serum miRNA-217 levels were analyzed by log-rank test. Univariate and multivariate Cox hazard regression model was employed to evaluate the prognostic factors for osteosarcoma.

**Results**

**Serum miR-217 expression in patients with osteosarcoma**

Serum miR-217 level was significantly downregulated in osteosarcoma patients compared with the healthy subjects (P<0.05, see Figure 1). Furthermore, ROC curve analysis revealed that serum miR-217 level could be used to distinguish osteosarcoma patients from healthy subjects, with a sensitivity of 68.6% and a specificity of 73.2%. The area under the curve (AUC) was 0.75 (95%CI:0.66-0.96, P<0.05, Figure 2).

**Relationship between Serum 217 and clinical characteristics**

The median value of serum miR-217 level in all 163 osteosarcoma patients was considered as the cut-off point to divide patients into the high miR-217 group (n=77) or low miR-217 group(n=86). The association between serum miR-217 levels and clinical characteristics were evaluated by using Chi-squared test. A statistically significant difference was observed between a high serum miR-217 levels and distance metastasis and clinical stage (both P<0.01, Table1). However, other clinical variables, including age, sex,
tumor site and size, and pathology were not closely associated with serum miR-217 expression (all \( p > 0.05 \)). (Table 1).

| Characteristic          | Serum miR-217 | \( p \) |
|-------------------------|---------------|--------|
|                         | High (n = 77) | Low (n = 86) |
| Age (years)             |               |        |
| \( \geq 25 \)          | 36            | 37     |
| \(< 25 \)              | 41            | 49     |
| Gender                  |               |        |
| Male                    | 54            | 67     |
| Female                  | 23            | 19     |
| Tumor site              |               |        |
| Tibia/femur             | 46            | 56     |
| other                   | 31            | 30     |
| Tumor size (cm)         |               |        |
| \( \geq 8 \)           | 33            | 36     |
| \(< 8 \)               | 44            | 50     |
| Distant metastasis      |               | \(< 0.01\) |
| Yes                     | 18            | 54     |
| No                      | 59            | 32     |
| Clinical stage          |               | \(< 0.01\) |
| IIA                     | 54            | 16     |
| IIB + III               | 23            | 70     |
| Pathology               |               |        |
| Osteogenic or chondrocytic | 46        | 62     |
| Fibrocytic or mixed     | 31            | 24     |

**Prognostic significance of serum miR-217 level in osteosarcoma patients**
The results of Kaplan–Meier method and log-rank test showed that patients with a low expression of serum miR-217 had a significantly poorer OS than those with a high expression of miR-217 (p=0.03, Figure 3.).

The univariate and multivariate analysis enrolled age and gender of patients, tumor size, distant metastasis, clinical stage, histological type and serum miR-217 level to determine independent prognostic indicator for osteosarcoma patients. After adjustment for potential confounders, a low serum miR-217 level (hazard ratio, 0.42; 95% confidence interval [CI]: 0.12–0.98, P<0.01) was also an independent predictive factor for survival outcome of osteosarcoma patients (Table 2.)

| The prognostic factor of osteosarcoma patients |
|-----------------------------------------------|
| **Univariate** | **Multivariate** |
| HR  | 95%CI | p  | HR  | 95%CI | p  |
|------|--------|-----|------|--------|-----|
| Age(years) | 1.21   | 0.72–2.26 | 0.52 | 0.68   | 0.22–0.96 | < 0.01 |
| Gender | 1.23   | 0.66–2.28 | 0.91 | 1.26   | 0.92–2.13 | < 0.01 |
| Tumor site | 1.01   | 0.52–1.62 | 0.84 | 1.26   | 0.92–2.13 | < 0.01 |
| Tumor size | 1.62   | 0.89–3.55 | 0.18 | 1.26   | 0.92–2.13 | < 0.01 |
| Distant metastasis | 0.72   | 0.32–0.99 | 0.02 | 0.68   | 0.22–0.96 | < 0.01 |
| Clinical stage | 1.68   | 1.01–4.28 | 0.01 | 1.26   | 0.92–2.13 | < 0.01 |
| Pathology | 1.22   | 0.71–2.27 | 0.63 | 1.26   | 0.92–2.13 | < 0.01 |
| Serum miR-101 | 0.49   | 0.22–0.99 | 0.03 | 0.42   | 0.12–0.98 | < 0.01 |

CI, confidence interval; HR, hazard ratio; miR-217, micro RNA-217.

Discussion

In this study, the results showed that the serum level of miR-217 was significantly decreased in osteosarcoma patients comparing with healthy participates. Moreover, serum miR-217 level can be used as a useful marker to discriminate osteosarcoma patients from healthy subjects. Furthermore, we evaluated the significance of serum miR-217 in predicting prognosis of osteosarcoma patients, and found that a low serum miR-217 level was significantly associated with shorter survival in osteosarcoma patients. We also observed a significant association between serum miR-217 level and classical unfavorable clinical characteristics for osteosarcoma patients. Based on such results, we suggested that miR-217 can be used as a diagnostic biomarker for osteosarcoma patients, which also can serve as a promising prognostic indicator.
MiR-217, as a novel tumor biomarker, play critical roles in biological process of cancer development\textsuperscript{26}. The miR-217 has been confirmed as a potential tumor suppressor in many malignancies including osteosarcoma\textsuperscript{27,28}. Shen et al. reported that miR-217 was decreased both in cancer cell lines and tissues, which was significantly correlated with distant metastasis, and functioned as a tumor suppressive miRNA and inhibits the osteosarcoma tumorigenesis through targeting WASF3\textsuperscript{29}. Moreover, miR-217 may be involved in inhibiting of tumor cells proliferation and metastasis through targeting KRAS oncogene\textsuperscript{30}. In our study, miR-217 was remarkably downregulated in osteosarcoma patients and significantly correlated with poor prognosis, which is consistent with the previous studies mentioned above.

However, the underlying function and origin of serum miR-217 in malignancy have not yet been fully understood. Several potential mechanisms for circulating miRNAs releasing have been reported, including passive leakage from cells in setting of chronic inflammation or injury, active secretion, complex formation with lipoproteins or RNA binding proteins\textsuperscript{31-33}. Yan \textit{et al.} reported that serum miR-217 expression was significantly decreased in acute myeloid leukemia (AML) patients compared to controls, which was identified as an independent marker for the diagnosis and prognosis of AML\textsuperscript{34}. It has been reported that low expressions of certain miRNAs were remarkably associated with advanced cancer stage\textsuperscript{35}. In this study, we found that low serum level of miR-217 was significantly associated with clinical stage of osteosarcoma patients, which is consistent with previous study\textsuperscript{36}.

Our study firstly reported that the downregulation of serum miR-217 level in a considerable scale osteosarcoma patients group, which can serve as a serum diagnostic and prognostic biomarker, as well as a novel therapeutic target for osteosarcoma. However, there were several limitations in this study. One limitation was a single center, small sample size and retrospective design of study. A large-scale, prospective and multicenter study is required to furtherly reevaluate such results. Furthermore, the underlying roles and mechanisms of miR-217 in development of osteosarcoma have not yet been fully evaluated. Future experiments are need to be performed to elucidate the mechanisms of serum miR-217 in carcinogenesis.

**Conclusions**

In this study, we found that serum miR-217 levels were downregulated in osteosarcoma patients. Moreover, low serum miR-217 level was significantly associated with poor survival of osteosarcoma patients, indicating that miR-217 acting as a tumor suppressor might not only serve as a diagnostic and prognostic indictor for osteosarcoma, but also a potential novel treatment target.

**List Of Abbreviations**

MiR, microRNA; RT-PCR, real-time quantitative reverse transcription polymerase chain reactions; ESS, Enneking staging system; OS, overall survival; ROC, receiver operating characteristic curve; AUC, area under the curve.
Declarations

Ethics approval and consent to participate:

This study was approved by the ethics committee of the First People's Hospital of Jiangxia District (No.20201029).

Consent for publication

All subjects have provided signed informed consent prior to enrollment.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

There was no funding for this study.

Authors' contributions

J.Y., Z.H.J., R. C., S. C. analyzed and interpreted the patient data, study concepts and manuscript editing. Y.J.R. and W.C.G. for manuscript editing and statistical analysis. H. H. for manuscript review. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Zhou J, Xiao X, Wang W, et al. Association between PTEN and clinical-pathological features of osteosarcoma. Biosci Rep. Jul 31 2019;39.
2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. Jun 11 2019.
3. Gao F, Xu F. Reduced expression of miR-564 is associated with worse prognosis in patients with osteosarcoma. Eur Rev Med Pharmacol Sci. Sep 2018;22:5851-5856.
4. Han X, Wang W, He J, et al. Osteopontin as a biomarker for osteosarcoma therapy and prognosis. Oncology letters. Mar 2019;17:2592-2598.
5. Simpson S, Dunning MD, de Brot S, et al. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. *Acta Vet Scand.* Oct 24 2017;59:71.

6. Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. *Eur J Cancer.* Mar 2019;109:36-50.

7. Ren L, Mendoza A, Zhu J, et al. Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. *Oncotarget.* Oct 6 2015;6:29469-29481.

8. Mohr AM, Mott JL. Overview of microRNA biology. *Semin Liver Dis.* Feb 2015;35:3-11.

9. Sheu-Gruttadauria J, Pawlica P, Klum SM, et al. Structural Basis for Target-Directed MicroRNA Degradation. *Mol Cell.* Jul 13 2019.

10. Jakob M, Mattes LM, Kuffer S, et al. MicroRNA expression patterns in oral squamous cell carcinoma: hsa-mir-99b-3p and hsa-mir-100-5p as novel prognostic markers for oral cancer. *Head Neck.* Jul 29 2019.

11. Kim DH, Khan H, Ullah H, et al. MicroRNA targeting by quercetin in cancer treatment and chemoprotection. *Pharmacol Res.* Jul 8 2019;147:104346.

12. Liu JB, Yan YJ, Shi J, et al. Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer. *Medicine (Baltimore).* Jul 2019;98:e16193.

13. Li Y, Sun H, Guan J, et al. Serum microRNA-381: A Potential Marker for Early Diagnosis of Gastric Cancer. *Yonsei Med J.* Aug 2019;60:720-726.

14. Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer.* Nov 2006;6:857-866.

15. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci U S A.* Jul 29 2008;105:10513-10518.

16. Ichikawa D, Komatsu S, Konishi H, et al. Circulating microRNA in digestive tract cancers. *Gastroenterology.* May 2012;142:1074-1078 e1071.

17. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A.* Mar 22 2011;108:5003-5008.

18. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol.* Apr 2011;13:423-433.

19. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. *Cancer Sci.* Oct 2010;101:2087-2092.

20. Zhang J, Wang T, Zhang Y, et al. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients. *Cancer Biomark.* 2018;21:763-768.

21. He S, Wang Z, Tang H, et al. MiR-217 Inhibits Proliferation, Migration, and Invasion by Targeting SIRT1 in Osteosarcoma. *Cancer Biother Radiopharm.* May 2019;34:264-270.

22. Jiang B, Zhu SJ, Xiao SS, et al. MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer. *Inflammation.* May 2 2019.
23. Li J, Li D, Zhang W. Tumor suppressor role of miR-217 in human epithelial ovarian cancer by targeting IGF1R. *Oncol Rep.* Mar 2016;35:1671-1679.

24. Lin Y, Cheng K, Wang T, et al. miR-217 inhibits proliferation, migration, and invasion via targeting AKT3 in thyroid cancer. *Biomed Pharmacother.* Nov 2017;95:1718-1724.

25. Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* Oct 1 2018;29:iv79-iv95.

26. Safaralizadeh R, Ajami N, Nemati M, et al. Disregulation of miR-216a and miR-217 in Gastric Cancer and Their Clinical Significance. *J Gastrointest Cancer.* Mar 2019;50:78-83.

27. Su J, Wang Q, Liu Y, et al. miR-217 inhibits invasion of hepatocellular carcinoma cells through direct suppression of E2F3. *Mol Cell Biochem.* Jul 2014;392:289-296.

28. Wang B, Qu XL, Liu J, et al. HOTAIR promotes osteosarcoma development by sponging miR-217 and targeting ZEB1. *J Cell Physiol.* May 2019;234:6173-6181.

29. Shen L, Wang P, Yang J, et al. MicroRNA-217 regulates WASF3 expression and suppresses tumor growth and metastasis in osteosarcoma. *PLoS One.* 2014;9:e109138.

30. Zhao WG, Yu SN, Lu ZH, et al. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. *Carcinogenesis.* Oct 2010;31:1726-1733.

31. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res.* Oct 2008;18:997-1006.

32. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci Signal.* Dec 8 2009;2:ra81.

33. Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. *Nucleic Acids Res.* Nov 2010;38:7248-7259.

34. Yan J, Wu G, Chen J, et al. Downregulated miR-217 expression predicts a poor outcome in acute myeloid leukemia. *Cancer Biomark.* 2018;22:73-78.

35. Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. *Adv Drug Deliv Rev.* Jan 2015;81:75-93.

36. Sun B, Yang M, Li M, et al. The microRNA-217 functions as a tumor suppressor and is frequently downregulated in human osteosarcoma. *Biomed Pharmacother.* Apr 2015;71:58-63.

**Figures**
Figure 1

Serum miR-217 level in osteosarcoma patients and healthy controls. The mean serum miR-217 level of 163 osteosarcoma patients was significant lower than that of 96 age-matched healthy volunteers (P<0.05).
Figure 2

Receiver-operator characteristic curve for osteosarcoma detection. ROC analysis showed a AUC of 0.75 for miR-217 with a 95% confidence interval between 0.66 and 0.96, P<0.05.
Figure 3

Lower serum miR-217 level was associated with poorer prognosis for osteosarcoma. The Log-rank analysis revealed that a low serum miR-217 level was significantly associated with a poor overall survival (P = 0.03).